9H-fluoren-9-ylmethyl 2-sulfanylpropanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9H-fluoren-9-ylmethyl 2-sulfanylpropanoate
• 化学式: C₁₇H₁₆O₂S
• 分子量: 284.4
• InChiKey: KXOPTFCJVNGIBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  27.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Hepatitis B antiviral agents
  申请人：Novira Therapeutics, Inc.

  公开号：US10196376B2

  公开（公告）日：2019-02-05

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种在有需要的个体中抑制、抑制或预防 HBV 感染的方法，包括向该个体施用治疗有效量的至少一种本发明化合物。
• Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10864217B2

  公开（公告）日：2020-12-15

  Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).

  本文提供了调节细胞凋亡抑制蛋白（IAPs）活性的化合物在治疗人类免疫缺陷病毒（HIV）中的用途，这些化合物可单独使用，也可与其他治疗剂联合使用。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Novira Therapeutics, Inc.

  公开号：US20170334882A1

  公开（公告）日：2017-11-23

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
• Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions
  申请人：Ralexar Therapeutics, Inc.

  公开号：US20170334897A1

  公开（公告）日：2017-11-23

  Described herein are liver X receptor (LXR) modulators and methods of milizing LXR modulators in the treatment of dermal diseasess, disorders or conditions. Also described herein are pharmaceutical compositions containg such compounds.
• ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20180216111A1

  公开（公告）日：2018-08-02

  The present disclosure relates to antisense oligomers and related compositions and methods for inducing exon inclusion as a treatment for glycogen storage disease type II (GSD-II) (also known as Pompe disease, glycogenosis II, acid maltase deficiency (AMD), acid alpha-glucosidase deficiency, and lysosomal alpha-glucosidase deficiency), and more specifically relates to inducing inclusion of exon 2 and thereby restoring levels of enzymatically active acid alpha-glucosidase (GAA) protein encoded by the GAA gene.